Rachel Humphrey

Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.

About Rachel Humphrey

The proxy statement of Black Diamond Therapeutics, Inc. reports total compensation of $2,979,288 for Rachel Humphrey in fiscal 2020, including a base salary of $144,621.

Summary generated from SEC filings and earnings-call records held by Equibles.

Research with Equibles

Turn this profile into a cited research brief

Start with a question tailored to the filings and events on this page, or connect Equibles financial data to ChatGPT or Claude.

Suggested question: “Explain Rachel Humphrey's disclosed executive compensation over time and cite the source filings.”

Use in your AI

Affiliation history

Recorded current and former roles; source labels appear when available.

Black Diamond Therapeutics, Inc. (BDTX)
Proxy statement

Start not stated–2021-04-27

Last confirmed by a filing; no departure on record

Company network

Recorded roles and call appearances connecting this person to public companies.

Black Diamond Therapeutics, Inc.

BDTX

Executive compensation

Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.

Fiscal year	Company	Role	Salary	Bonus	Stock awards	Option awards	Incentive	Other	Total
2020	Black Diamond Therapeutics, Inc. (BDTX)	Chief Medical Officer	$144,621	$25,000	$281,400	$2,469,000	$49,000	$10,267	$2,979,288

Recent activity

No call appearances or filed executive changes recorded yet.